Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept.
about
Molecular phenotypes in triple negative breast cancer from African American patients suggest targets for therapyTumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid ClassesBRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations.Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer.Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers.Cytosolic phospholipase A2-α expression in breast cancer is associated with EGFR expression and correlates with an adverse prognosis in luminal tumours.Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness.MUTYH gene variants and breast cancer in a Dutch case–control study.Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers.Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancerThe Role of PIWIL4, an Argonaute Family Protein, in Breast CancerAberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical featuresSomatic copy number changes in DPYD are associated with lower risk of recurrence in triple-negative breast cancers.Biomarkers for Basal-like Breast Cancer.Understanding the biology of triple-negative breast cancer.Challenges in the development of future treatments for breast cancer stem cells.P16 but not retinoblastoma expression is related to clinical outcome in no-special-type triple-negative breast carcinomas.Next Generation Sequencing Reveals High Prevalence of BRCA1 and BRCA2 Variants of Unknown Significance in Early-Onset Breast Cancer in African American Women.BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potentialThe BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.RAGE receptor targeted bioconjuguate lipid nanoparticles of diallyl disulfide for improved apoptotic activity in triple negative breast cancer: in vitro studies.Development of metastatic HER2(+) breast cancer is independent of the adaptive immune system.Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC).How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment.
P2860
Q28535227-1C75E7C0-8B61-4B47-8637-6F0B70328B4EQ28554412-CD08D164-C9D9-4E17-84E9-9BED2EF1D69DQ30497664-A48E0AFE-4936-43DD-AFFA-B10132557591Q33584322-BAA0F728-5980-43EB-A9CB-C9A1999D316FQ33757796-D595A0A7-59CA-400A-9317-6EAC7FB5FF94Q34543740-43A39B00-7295-473B-8DD9-C94EF66A5CF0Q35683623-B0283C70-C1E9-4C8E-B447-E71F6803AD4EQ36095933-DDC7D033-9F43-47D7-93A5-9E92F293B49BQ36132338-B9B53928-BD3F-4C18-9E07-727768724DACQ36853817-980D557E-3766-49CD-BB61-6B09B5F023CCQ36898235-E72E5673-041F-4928-8EEF-F8C4DC1C8317Q36914825-8C5E8845-E090-4CDF-9A00-6C7EE16C6292Q37279312-87C94044-3D63-4E3E-B248-339F225FA823Q37328394-1F082780-D860-4C85-83C7-B65F7BF78555Q38046574-1775870A-81E4-40F2-8C28-F12642E3D707Q38239121-5AD41B7E-DD5E-4ED7-A077-B7106000D37FQ38395549-EDBDD024-BA34-4670-9B3C-599B4D95CCA3Q38691342-18B0D15F-2961-4ACC-B16F-BE745DEEA5C7Q40907759-12658676-D4D6-4645-A2B9-FBB19A495BA8Q41542872-B9B9B59B-7315-4010-BCEF-A852ACFE5B93Q51053600-16BB5B0A-20DF-4F27-A286-62DA4626B430Q53255022-26E83C07-F65E-414B-B2E6-58A57F0BE163Q53446414-4738DF69-F50C-49CA-B99A-DF2484E628A3Q55316580-22406151-9297-4172-AEFD-C2C97D54449A
P2860
Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical relevance of the trip ...... inical utility of the concept.
@en
Clinical relevance of the trip ...... inical utility of the concept.
@nl
type
label
Clinical relevance of the trip ...... inical utility of the concept.
@en
Clinical relevance of the trip ...... inical utility of the concept.
@nl
prefLabel
Clinical relevance of the trip ...... inical utility of the concept.
@en
Clinical relevance of the trip ...... inical utility of the concept.
@nl
P1476
Clinical relevance of the trip ...... inical utility of the concept.
@en
P2093
Laura J Van 't Veer
Sabine C Linn
P356
10.1016/S0959-8049(09)70012-7
P478
45 Suppl 1
P577
2009-09-01T00:00:00Z